Talks on expanding coverage on Tecentriq to start soon

By Eo, Yun-Ho | translator Byun Kyung A

21.02.18 16:43:14

가나다라 0

Cancer Deliberation Committee to deliberate the agenda on Feb. 24, could be a first immunotherapy option

Both diseases have highly unmet medical needs, but the government and the company negotiation would be the key

An immunotherapy Tecentriq (atezolizumab) is to face the first threshold to expand the National Health Insurance (NHI) reimbursement in treating patients with either triple-negative breast cancer (TNBC) or hepatocellular carcinoma.

A pharmaceutical industry source reported the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee would be convened on Feb. 24 to deliberate Roche Korea’s programmed death-ligand 1 (PD-L1) inhibiting immunotherapy Tecentriq seeking to expand reimbursement on indication to treat patients with TNBC and hepatocellular carcinoma.

Last year, Tecentriq, in combination with nanoparticle albumin-bound (nab) paclitaxel, won the South Ko

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)